Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 4/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 8/20 | 0.37 |
| ▸ | TGFBR2 | P37173 | 3/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.36 |
| ▸ | CCR1 | P32246 | 1/20 | 0.35 |
| ▸ | CCR8 | P51685 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.32 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30099428 | 0.83 | DGAT1 (0.41) | DGAT1TGFBR1TGFBR2PDE10ACCR1 | |
| SCHEMBL31469288 | 0.79 | DGAT1 (0.42) | DGAT1MAPK14BRD4CREBBP | |
| SCHEMBL19806370 | 0.79 | DGAT1 (0.37) | DGAT1TGFBR1PDE10ACCR1CCR8 | |
| SCHEMBL5197940 | 0.78 | DGAT1 (0.39) | DGAT1TGFBR1TGFBR2PDE10AMAPK14 | |
| SCHEMBL23389773 | 0.78 | TGFBR1 (0.38) | DGAT1TGFBR1TGFBR2MAPK14BRD4 | |
| SCHEMBL29796722 | 0.78 | TGFBR1 (0.38) | DGAT1TGFBR1TGFBR2MAPK14BRD4 | |
| SCHEMBL23389504 | 0.78 | TGFBR1 (0.38) | DGAT1TGFBR1TGFBR2MAPK14BRD4 | |
| SCHEMBL29796627 | 0.78 | TGFBR1 (0.38) | DGAT1TGFBR1TGFBR2MAPK14BRD4 | |
| SCHEMBL29796667 | 0.78 | TGFBR1 (0.38) | DGAT1TGFBR1TGFBR2MAPK14BRD4 | |
| SCHEMBL23389954 | 0.78 | TGFBR1 (0.38) | DGAT1TGFBR1TGFBR2MAPK14BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250215017-A1 | TGF-ß INHIBITOR COMPOUND AND USE THEROF | MEDINNO PHARMACEUTICAL TECHNOLOGY (ZHUHAI) CO., LTD. (CN) | 2025-07-03 | — | — | US | disclosed |
| US-20250179094-A1 | TGF-B INHIBITOR COMPOUND AND USE THEREOF | MEDINNO PHARMACEUTICAL TECHNOLOGY (ZHUHAI) CO., LTD. (CN) | 2025-06-05 | — | — | US | disclosed |
| EP-4556478-A1 | TGF-BETA INHIBITOR COMPOUND AND USE THEREOF | Medinno Pharmaceutical Technology (Zhuhai) Co., Ltd. (CN) | 2025-05-21 | — | — | EP | disclosed |
| EP-4556477-A1 | TGF-BETA INHIBITOR COMPOUND AND USE THEREOF | Medinno Pharmaceutical Technology (Zhuhai) Co., Ltd. (CN) | 2025-05-21 | — | — | EP | disclosed |
| CN-117534686-A | TGF-beta inhibitor compounds and uses thereof | 河南迈英诺医药科技有限公司 | 2024-02-09 | — | — | CN | disclosed |
| CN-117534675-A | TGF-beta inhibitor compounds and uses thereof | 河南迈英诺医药科技有限公司 | 2024-02-09 | — | — | CN | disclosed |
| WO-2022251359-A1 | BICYCLIC INHIBITORS OF ALK5 AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179094-A1 | TGF-B INHIBITOR COMPOUND AND USE THEREOF | TGFB1, TGFB2, TGFBR1 | DGAT1 4536/4885TGFBR1 3/4885TGFBR2 4/4885 |
| US-20250215017-A1 | TGF-ß INHIBITOR COMPOUND AND USE THEROF | TGFB1, TGFB2, TGFBR2 | DGAT1 3841/4885TGFBR1 4/4885TGFBR2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.